GlassScriptPhysician profile
Jack G Hudson
NPI 1326152232
$3,641.98
in general payments reported to CMS, 2019-2025
28 companies · $19.73 in 2025
The $19.73 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $462 · 2022: $862 · 2023: $1,145 · 2024: $104 · 2025: $19.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.32 | 2019-2024 | |
| Amgen INC. | $284.42 | 2019-2024 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $249.69 | 2022-2024 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.56 | 2019-2023 | Jardiance |
| Pfizer INC. | $218.61 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.06 | 2019-2023 | Trintellix |
| Tris Pharma INC | $204.75 | 2022-2024 | Dyanavel Xr |
| Novo Nordisk INC | $188.71 | 2019-2023 | Wegovy, Saxenda |
| Merck Sharp & Dohme LLC | $171.11 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $167.43 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.99 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $122.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $82.59 | 2019-2023 | |
| Abbott Laboratories | $73.72 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $72.83 | 2022-2023 | |
| Genentech USA, INC. | $62.96 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $61.95 | 2019-2020 | |
| Glaxosmithkline, LLC. | $61.17 | 2020-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Idorsia Pharmaceuticals US INC | $57.95 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $41.70 | 2019-2020 | |
| Allergan, INC. | $31.15 | 2020 | |
| Amneal Pharmaceuticals LLC | $28.95 | 2023 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $28.33 | 2019 | |
| Roche Diabetes Care, INC. | $28.00 | 2019 | |
| Shionogi INC | $15.33 | 2019 | |
| Ibsa Pharma INC. | $12.70 | 2023 | Tirosint, Licart |
| Shire North American Group INC | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.